Following their earlier work on nitric oxide (NO) releasing oleanolic acid (OA) derivatives as therapeutic agents for human hepatocellular carcinoma (HCC) – the third leading cause of cancer death worldwide without effective chemotherapy – Prof. Yihua Zhang and coll. at the Center of Drug Discovery, China Pharmaceutical University (Nanjing, P.R. China) have designed a series of glycosylated diazeniumdiolate derivatives of oleanolic acid.
One of the coupounds has been found to selectively inhibit the proliferation of HCC in vivo but not that of non-tumor liver cells, with relatively low acute toxicity, and may be a promising drug candidate against HCC.
The authors also provide an in-depth analysis of the mechanisms underlying the action of this group of glycosylated diazeniumdiolate-based OA derivatives…
Want to know more? Why not read now, the article will be FREE to access to all for the next four weeks
Glycosylated diazeniumdiolate-based oleanolic acid derivatives: synthesis, in vitro and in vivo biological evaluation as anti-human hepatocellular carcinoma agents
Zhangjian Huang, Junjie Fu, Ling Liu, Yijun Sun, Yisheng Lai, Hui Ji, Edward E. Knaus, Jide Tian and Yihua Zhang
Org. Biomol. Chem., 2012, Advance Article
DOI: 10.1039/C2OB25252J, Paper
